ClinicalTrials.gg
CompletedNCT02537405Updated Sep 1, 2015

Bioequivalence Study of Rivaroxaban in Japanese Healthy Adult Male Subjects

A Phase 1 interventional study of Rivaroxaban (BAY 59-7939) and Rivaroxaban (Xarelto, BAY 59-7939) in Embolism, Atrial Fibrillation and Venous Thrombosis, sponsored by Bayer. Completed at 1 site in Japan. Open to male participants aged 20 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-09-01.

Sponsored by Bayer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Embolism by Bayer — none open to participants now, none under way, none of them phase 3. Embolism · Bayer.

Started
2014
with 1 other
Phase 1
3 of 11
none open now
Registered
8th of 11
by date

Among the 11 studies in Embolism by Bayer, this one is one of 2 that started in 2014, is one of 3 in phase 1, and was the 8th registered.

Embolism

104 studies on the registry are indexed under Embolism; 14 are open to participants now.

Browse Embolism studies →

Open to participants now

None of the 11 studies in Embolism by Bayer is open now. The open studies under Embolism, anywhere →

Who these studies take

Of the 9 Embolism studies recruiting now, 7 set no upper age limit and none stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 20 Years to 40 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Embolism by Bayer as a file.
02

Study summary

The objectives of this study are to establish the bioequivalence between rivaroxaban tablet 10mg and rivaroxaban granule formulation 10mg, and to assess the safety and tolerability of rivaroxaban 10mg in healthy adult male subjects.

03

Conditions studied

  • Embolism, Atrial Fibrillation and Venous Thrombosis
04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese healthy male subjects
  • 20 to 40 years of age
  • 17.6 to 26.4 kg / m² of (BMI)

Exclusion criteria

Exclusion Criteria:

  • Subject with incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study drugs will not be normal
  • Subject with a history of relevant diseases of vital organs, of the central nervous system or other organs, eg instable coronary heart disease, heart failure, liver failure, kidney failure, hypotension, or history of stroke or myocardial infarction
  • Subject with known coagulation disorders (eg von Willebrand's disease, hemophilia)
  • Subject with known disorders with increased bleeding risk (eg periodontosis, hemorrhoids, acute gastritis, peptic ulcer)
  • Subject with known sensitivity to common causes of bleeding (eg nasal)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    BAY59-7939 granule

    Drug: Rivaroxaban (BAY 59-7939)

  • Active comparator
    BAY59-7939 tablet

    Drug: Rivaroxaban (Xarelto, BAY 59-7939)

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax (maximum observed drug concentration in measured matrix after single dose administration)

    Time frame: Multiple time point up to 3 day

  2. AUC(0-tlast) (AUC from time 0 to the last data point > LLOQ (lower limit of quantitation))

    Time frame: Multiple time point up to 3 day

Secondary outcomes

  1. Number of participants with adverse events as a measure of safety and tolerability

    Time frame: Up to 30 day

07

Study locations

1 site
  • Kumamoto, 861-4157, Japan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2014, a primary completion of Mar 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2015
First posted
Sep 1, 2015
Start
Feb 2014
Primary completionActual
Mar 2014
CompletionActual
Apr 2014
Last update
Sep 1, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02537405
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Sep 1, 2015
Start date
Feb 2014
Primary completion
Mar 2014
Completion
Apr 2014
Last update
Sep 1, 2015

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rivaroxaban

Start the discussion